Keywords: Almirall, Forest, COPD, Aclidinium, Clinical studies

Almirall and Forest say their COPD drug aclidinium shows positive results and Ph III and Ph II studies

Article | 06 January 2011

Print This

Spain’s largest drugmaker Almirall (ALM.MC) and US partner Forest Laboratories, (NYSE: FRX) have announced positive top-line results ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in